secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001628280-23-005333
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q4 2022 net revenue $28.4M (+21% YoY); FY net revenue $134.0M (+194% YoY); net loss $0.18/share
--------------------------------------------------------------------------------

- Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.
- Net loss Q4 $26.0M ($0.18/share); FY net loss $108.2M ($0.76/share).
- Cash, equivalents and investments $389.4M at Dec 31, 2022.
- FY 2023 net product revenue guidance reiterated at $120-140M.
- Approx. 1,525 patients on LUPKYNIS therapy at year-end; 274 PSFs secured through Feb 24, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/0001628280-23-005333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/auph-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer